CFOR (CFOR) Stock Price & Analysis
CFOR (CFOR) rose 0.00% to USD 0.5 as of June 10, 2026 at 03:05 UTC, according to Nexqual real-time market data.
CFOR last closed at USD 0.5; the session ranged USD 15.16–23.5 on volume of 962 shares. Market capitalization is $6.09M, with a 52-week range of USD 0–34 (PNK). Source: Nexqual, June 10, 2026 at 03:05 UTC.
Key Statistics (as of June 10, 2026 at 03:05 UTC)
| Price | USD 0.5 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.5 |
| Open | USD 15.16 |
| Day Range | USD 15.16 – 23.5 |
| 52-Week Range | USD 0 – 34 |
| Volume | 962 shares |
| Market Cap | $6.09M |
| Exchange | PNK |
Technical Analysis (CFOR)
Nexqual's technical model rates CFOR "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 75.65 (overbought) |
| vs SMA50 | Below (USD 6.89) |
| MACD | -1.24 (negative) |
Analyst Ratings (CFOR)
Wall Street analysts rate CFOR "None", per Nexqual as of June 10, 2026 at 03:05 UTC.
| Consensus Rating | None |
|---|
Earnings (CFOR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -4.6 vs est -4.3 ▼ miss |
| 2023-06-30 | USD -9.3 vs est -7.1 ▼ miss |
| 2022-12-31 | USD -18.97 vs est -20 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Financials & Fundamentals (CFOR)
| Total Revenue | $30.20M |
|---|---|
| Revenue Growth (YoY) | +424.00% |
| Gross Margin | +90.00% |
| Operating Margin | +83.40% |
| Profit Margin | +78.21% |
| ROE | +120.40% |
| Debt / Equity | 5.8 |
| Current Ratio | 0.22 |
| Total Cash | $531,277 |
| Total Debt | $1.85M |
| Free Cash Flow | $20.27M |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Financial Health Score (CFOR)
Nexqual rates CFOR's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:05 UTC.
| Growth | Critical — Revenue -39% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $531K cash vs $2M debt |
| Cash Flow | Strong — FCF $20M, 777% margin |
| Efficiency | Strong — ROE 120%, ROA 62.7% |
Ownership (CFOR)
| Insider Ownership | +87.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 12.18M |
| Float | 3.82M |
| Short % of Float | +1.79% |
Source: Nexqual, June 10, 2026 at 03:05 UTC.
Leadership (CFOR)
CFOR is led by Christian-Laurent Benoit Bonte (age 46), Chief Executive Officer, per Nexqual as of June 10, 2026 at 03:05 UTC.
| Chief Executive Officer | Christian-Laurent Benoit Bonte (age 46) |
|---|---|
| Chief Operating Officer | Mohd Azham bin Azudin (age 52) |
| Chief Technology Officer | Syed Johan Bin Syed Mohd (age 36) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AYTU | Aytu BioPharma, Inc. | USD 2.3 | ▲ 2.22% |
| PRPO | Precipio, Inc. | USD 23.32 | ▼ 0.72% |
| TENX | Tenax Therapeutics, Inc. | USD 10.73 | ▲ 0% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| AIM | AIM ImmunoTech Inc. | USD 0.4 | ▼ 22.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:05 UTC. This page is informational and not investment advice.